<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363479</url>
  </required_header>
  <id_info>
    <org_study_id>PALO-10-01</org_study_id>
    <nct_id>NCT01363479</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting</brief_title>
  <official_title>Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of
      palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic
      drug), both given with oral dexamethasone. The objective of the study is to demonstrate that
      oral palonosetron 0.50 mg is as effective as (non-inferior to) palonosetron IV 0.25 mg to
      prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24
      hours after administration of a single cycle of highly emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With no Emesis</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With no Rescue Medication</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">743</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Oral palonosteron plus dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I.V. palonosetron plus dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral palonosetron</intervention_name>
    <arm_group_label>Oral palonosteron plus dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I.V. palonosetron</intervention_name>
    <arm_group_label>I.V. palonosetron plus dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Oral palonosteron plus dexamethasone</arm_group_label>
    <arm_group_label>I.V. palonosetron plus dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy is permitted.

          -  Diagnosed with a malignant solid tumor and scheduled to receive first course of
             cytotoxic chemotherapy with cisplatin administered as a single I.V. dose of equal or
             more than 70 mg/m2 over 1-4 hours on study Day 1, either alone or in combination with
             other chemotherapeutic agents.

          -  If scheduled to receive combination regimens, non-cisplatin agents of moderate to high
             emetogenic potential are allowed and they must be administered following the cisplatin
             infusion and completed no more than 6 hours after the initiation of cisplatin
             infusion.

          -  If scheduled to receive chemotherapy agents of minimal to low emetogenic potential,
             they are to be given on Day 1 following cisplatin or on any subsequent study day.

          -  ECOG Performance Status of 0, 1, or 2

          -  Female patients of either non-childbearing potential or child-bearing potential with a
             commitment to use contraceptive methods throughout the clinical trial

          -  Hematologic and metabolic status adequate for receiving a highly emetogenic
             cisplatin-based regimen based on laboratory criteria (Neutrophils,Platelets,
             Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance)

          -  If a patient has a known hepatic or renal impairment, he/she may be enrolled in this
             study at the discretion of the Investigator.

          -  If a patient has a known history or predisposition to cardiac conduction interval
             abnormalities he/she may be enrolled in this study at the discretion of the
             Investigator.

        Exclusion Criteria:

          -  If female, pregnant or lactating.

          -  Current use of illicit drugs or current evidence of alcohol abuse.

          -  Scheduled to receive moderately emetogenic chemotherapy (MEC) or HEC from Day 2 to Day
             5 following cisplatin administration.

          -  Received or is scheduled to receive radiation therapy to the abdomen, or the pelvis
             within 1 week prior to Day 1 or between Days 1 to 5.

          -  Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.

          -  Symptomatic primary or metastatic CNS malignancy.

          -  Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial
             pressure, hypercalcemia, an active infection or any uncontrolled medical conditions
             (other than malignancy) that, in the opinion of the investigator, may confound the
             results of the study, represent another potential etiology for emesis and nausea
             (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks
             in administering the study drugs to the patient.

          -  Known hypersensitivity or contraindication to 5-HT3 receptor antagonists (e.g.,
             palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron) or
             dexamethasone.

          -  Participation in a clinical trial involving palonosetron.

          -  Any investigational drugs (other than those given in this study) taken within 4 weeks
             prior to Day 1, and/or is scheduled to receive any investigational drug during the
             study.

          -  Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1. However
             topical and inhaled corticosteroids with a steroid dose of £ 10 mg of prednisone daily
             or its equivalent are permitted.

          -  Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.

          -  Any medication with known or potential antiemetic activity within 24 hours prior to
             Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genesis Cancer Centre</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Center</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Centre Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facey Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center, LLC</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Medical Associates-Oncology and Hematology</name>
      <address>
        <city>Bristol</city>
        <state>Rhode Island</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Utah Associates [Hematology/ Oncology]</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico Integral (COI)</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico de Córdoba (IONC)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5006HBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria Reina Fabiola</name>
      <address>
        <city>Córdoba</city>
        <zip>X5004FHP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico CER [Oncology]</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000AIK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISIS Clinica Especializada</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Tota Venkova</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatement of Oncology Diseases - Sofia District Medical Oncology Department</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Tsaritsa Yoanna - ISUL&quot; Ltd.Medical Oncology Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1572</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialised Hospital for Active treatment on Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Dispensery for Oncology Diseases with in-patient</name>
      <address>
        <city>Sofia</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Centre</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar [Oncology]</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bolnica Varazdin</name>
      <address>
        <city>Varazdin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka bolnica [Sestre milosrdnice]</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Onkologie und Hämatologie Universitätsmedizin Charité Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld UG</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München</name>
      <address>
        <city>München</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen Neuperlach</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Kútvölgyi Klinikai Tömb</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fővárosi Önkormányzat Uzsoki utcai Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Megyei Oktató Kórház</name>
      <address>
        <city>Györ</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Önkormányzat Kórháza, Szeged</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem [Onkoterápiás Intézet]</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Venkateshwara Hospital [Medical Oncology]</name>
      <address>
        <city>Bangalore</city>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinmaya Mission Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Super speciality Hospital</name>
      <address>
        <city>Hyderabad Andhra Pradesh</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sujan Surgical Cancer Hospital and Amracvati Cancer Foundation</name>
      <address>
        <city>Maharashtra</city>
        <zip>444605</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>Tamil Nadu</city>
        <zip>600035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Cancer Centre [Surgical and Medical Oncology]</name>
      <address>
        <city>Vijayawada</city>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi - ASL Lecce</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;Alessandro Manzoni&quot;</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Regionale S.Carlo di Potenza</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki Zespolony</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M.Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego</name>
      <address>
        <city>Lomza</city>
        <zip>18-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. J. Korczaka</name>
      <address>
        <city>Slupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Magodent - Centrum Medczyne Ostrobramska</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta &quot;Dr. Constantin Opris&quot;</name>
      <address>
        <city>Baia-Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic &quot;Prof. Dr. Alex. Trestioreanu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic &quot;Prof. Dr. Ion Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj (Oncologie Medicala)</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Euroclinic</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sibiu [Oncologie]</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Arkhangelsk Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO Krasnoyarsk State Medical University n.a. prof. V.F.</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Lipetsk Regional Oncology Dispensary [General Oncology]</name>
      <address>
        <city>Lipetsk</city>
        <zip>398005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Regional Oncology Dispensary #2</name>
      <address>
        <city>Magnitogorsk</city>
        <zip>455001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAMN - Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin RAMN</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBUZ City Clinical Hospital #1 [Oncology]</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBU &quot;Medical Radiology Scientific Center of Minzdravsotsrazvitiya RF</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Med. Univer. n.a. I.I.Pavlov based Ryazan Regio</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Leningrad Regional Oncological Dispensary</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Clinical Oncology Dispesary</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi likuvalno-profilaktychnyi zaklad &quot;Chernigivskyi</name>
      <address>
        <city>Chernigiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi zaklad Miska bahatoprofilna klinichna likarnia #4</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalno-klinichnyi likuvalno-profilaktychnyi zaklad</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DU IMR AMNU [vd khemter]</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chmelnytskyi Regional Clinical Oncology Centre [Oncology]</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <results_first_submitted>November 6, 2014</results_first_submitted>
  <results_first_submitted_qc>November 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2014</results_first_posted>
  <disposition_first_submitted>January 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2013</disposition_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 743 patients were randomized (ITT population), 739 received study medications (oral or I.V. palonosetron plus dexamethasone, safety population), 738 received study medications (oral or I.V. palonosetron plus dexamethasone, safety population) and chemotherapy (FAS population)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Palonosteron Plus Dexamethasone</title>
          <description>Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
Oral palonosetron
Dexamethasone</description>
        </group>
        <group group_id="P2">
          <title>I.V. Palonosetron Plus Dexamethasone</title>
          <description>Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
I.V. palonosetron
Dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="371">number of randomised patients</participants>
                <participants group_id="P2" count="372">number of randomised patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population ie patients receiving either oral or IV palonosetron plus dexamethasone</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Palonosteron Plus Dexamethasone</title>
          <description>Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
Oral palonosetron
Dexamethasone</description>
        </group>
        <group group_id="B2">
          <title>I.V. Palonosetron Plus Dexamethasone</title>
          <description>Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
I.V. palonosetron
Dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="370"/>
            <count group_id="B2" value="369"/>
            <count group_id="B3" value="739"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="9.41"/>
                    <measurement group_id="B2" value="57.7" spread="9.92"/>
                    <measurement group_id="B3" value="57.9" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication</title>
        <time_frame>0-24 hours</time_frame>
        <population>Full Analysis Set i.e. patients receiving study drugs and chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Palonosteron Plus Dexamethasone</title>
            <description>Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
Oral palonosetron
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>I.V. Palonosetron Plus Dexamethasone</title>
            <description>Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
I.V. palonosetron
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication</title>
          <population>Full Analysis Set i.e. patients receiving study drugs and chemotherapy</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" lower_limit="85.9" upper_limit="92.2"/>
                    <measurement group_id="O2" value="86.2" lower_limit="82.3" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis was rejected (and non inferiority of oral palonosetron 0.50 mg versus I.V. palonosetron 0.25 mg demonstrated), if the lower limit of the 2 sided 99% CI for the difference in proportion of patients with CR (risk difference) was greater (i.e., closer to zero) than 15%.Study had 90% power.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.21</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.74</ci_lower_limit>
            <ci_upper_limit>9.17</ci_upper_limit>
            <estimate_desc>The risk difference and the 99% CI calculation were performed using a 2 sided stratum adjusted Cochran Mantel Haenszel (CMH) test including gender and region as strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With no Emesis</title>
        <time_frame>0-24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With no Rescue Medication</title>
        <time_frame>0-24 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period starting from the time of informed consent signature until 21 days post study drugs administration on Day 1.</time_frame>
      <desc>Based on the medical judgment of the investigator, all non resolved, non serious AEs beyond this date could have been followed for an additional 14 days. At the end of this additional follow up period, all unresolved AEs were documented on the eCRF as “ongoing.”</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Palonosteron Plus Dexamethasone</title>
          <description>Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
Oral palonosetron
Dexamethasone</description>
        </group>
        <group group_id="E2">
          <title>I.V. Palonosetron Plus Dexamethasone</title>
          <description>Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
I.V. palonosetron
Dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Aphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Proctitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Laryngotracheal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor and investigator(s) agree that no publications discussing trials' results will occur until release of final report. Sponsor has no objections if the investigators publish study results, however the investigator is requested to contact the sponsor before publishing, to prevent premature disclosure of data and is not intended as a restrictive measure concerning results or opinions of investigators.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marco Palmas MD, Head of Clinical Development</name_or_title>
      <organization>Helsinn Healthcare SA</organization>
      <phone>+41919852121</phone>
      <email>marco.palmas@helsinn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

